The treatment is given as an intravenous infusion, which means it is delivered through a vein. The study looks at whether the new drug combination can help keep the cancer from coming back and whether it can remove all signs of invasive cancer in the breast and nearby lymph nodes before surgery. The course of the study includes treatment over a planned period, followed by surgery and later follow-up visits to monitor health over time.

Some medical terms used in the study include neoadjuvant, which means treatment given before surgery, and EFS, which means the length of time without a cancer-related event such as the cancer returning or worsening. The study also records side effects and overall health changes during follow-up.

Participants may receive elacestrant, which is a type of medication used to block the effects of hormones that help cancer grow. Some individuals might also be given ribociclib, a medication known as a CDK4/6 inhibitor that helps stop cancer cells from dividing. The treatments are administered as oral use tablets. Depending on the group assigned, some participants may receive these medications alone or in combination with other standard hormone therapies, and some may receive a placebo.

The study follows participants over a period of time to monitor how they respond to the different medication combinations. The process involves tracking long-term outcomes, such as overall survival, which is the length of time from the initial diagnosis until death, and disease-free survival, which measures the time during and after treatment that a person lives without any signs or symptoms of the cancer. The researchers will also look at how the treatments affect the quality of life and any side effects that may occur during the study period.

The trial is testing a combination of two treatments: pembrolizumab and olaparib. Pembrolizumab is a type of medicine called a PD-1 inhibitor, which helps the immune system recognize and attack cancer cells. Olaparib is a PARP inhibitor, which helps prevent cancer cells from repairing themselves, leading to their death. The purpose of the study is to see how effective this combination is in treating the cancer. Participants will receive these treatments over a period of 27 weeks, and their response to the treatment will be monitored.

Throughout the study, researchers will observe how well the cancer responds to the treatment, how long the response lasts, and how long patients live without the cancer getting worse. They will also monitor any side effects or serious health issues that may occur. This information will help determine if the combination of pembrolizumab and olaparib is a beneficial treatment option for patients with this specific type of breast cancer.

The study compares two treatment approaches: patients will receive either sacituzumab govitecan or a standard treatment chosen by their doctor from several options including carboplatin, cisplatin, or capecitabine. The purpose is to determine if sacituzumab govitecan is more effective at preventing the cancer from returning compared to standard treatments.

Treatment will continue for up to 24 months. The medications are given either through an intravenous infusion directly into the bloodstream or as tablets taken by mouth, depending on which treatment the patient receives. All patients must have completed their previous treatments, including surgery and radiation therapy, before starting the study medication.

The purpose of the study is to see if the combination of sacituzumab govitecan and pembrolizumab is more effective than sacituzumab govitecan alone. Participants in the study will receive one of these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will last for up to 18 months, during which time participants will receive regular treatments and follow-up care to monitor their health and the effectiveness of the treatment.

Throughout the study, doctors will check for the absence of cancer in the breast and lymph nodes, which is known as a complete response. They will also track the participants’ health over three years to see if the cancer stays away. The study aims to improve treatment options for people with this type of breast cancer and to increase the chances of long-term health and recovery.

Participants in the study will receive these medications through infusions or injections over a period of time. The study will monitor how the cancer responds to these treatments and assess the long-term outcomes for the patients. The goal is to determine the effectiveness of the treatment in reducing the size of the tumor and improving the chances of successful surgery. The study will also look at the safety of the treatments and their impact on the quality of life of the participants.

Throughout the study, various aspects such as the clinical and radiological response of the cancer, the characteristics of the tumors, and the survival rates of the patients will be evaluated. The study will also consider the frequency of breast-conserving surgeries and the overall safety of the treatment regimen. This research is part of a larger effort to improve treatment strategies for patients with HER2-positive breast cancer.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.